Rani Therapeutics RaniPill platform joins FDA Emerging Technology Program
Bitget2026/10/05 12:11Rani Therapeutics’ RaniPill Capsule platform was accepted into the FDA’s Emerging Technology Program under CDER. Acceptance enables early FDA engagement on technical and regulatory issues tied to the platform’s product design and manufacturing. FDA interactions can cover broader platform use beyond individual drug products, supporting plans to automate manufacturing ahead of wider clinical use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839222) on October 05, 2026, and is solely responsible for the information contained therein.
- Rani Therapeutics’ RaniPill Capsule platform was accepted into the FDA’s Emerging Technology Program under CDER.
- Acceptance enables early FDA engagement on technical and regulatory issues tied to the platform’s product design and manufacturing.
- FDA interactions can cover broader platform use beyond individual drug products, supporting plans to automate manufacturing ahead of wider clinical use.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal
Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch
Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?
Crypto prices
More
